Securities code: 002513 securities abbreviation: Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) Announcement No.: 2022-009 Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513)
Announcement of the resolution of the first extraordinary general meeting of shareholders in 2022
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Special tips:
1. The shareholders’ meeting did not veto the proposal.
2. This general meeting of shareholders does not involve changing the resolution of the previous general meeting of shareholders.
2、 Meetings held
1. Meeting method: this extraordinary general meeting of shareholders adopts the combination of on-site voting and online voting.
2. Meeting time
(1) The on-site meeting will be held at 14:00 p.m. on Tuesday, January 18, 2022.
(2) Online voting time: January 18, 2022. Among them, the specific time of online voting through the trading system of Shenzhen stock exchange is: 9:15 ~ 9:25, 9:30 ~ 11:30 and 13:00 ~ 15:00 on January 18, 2022; The specific time of voting through the Internet voting system of Shenzhen stock exchange is any time from 9:15 a.m. to 15:00 p.m. on January 18, 2022.
3. Venue of the on-site meeting: conference room of the company, No. 2, Ningxia road, Xinyi economic development zone.
4. Convener: Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) board of directors
5. Moderator: Mr. Liu Zhi, chairman
6. Equity registration date: Thursday, January 13, 2022
7. The convening of this shareholders’ meeting complies with relevant laws, administrative regulations, departmental rules, normative documents and the articles of association.
3、 Attendance at the meeting
1. Overall attendance at the meeting
A total of 20 shareholders (or agents authorized by shareholders) attended the meeting, with 133663852 representative shares, accounting for 39.3029% of the total voting shares on the equity registration date of the company.
2. On site attendance
There were 6 shareholders and authorized representatives of shareholders attending the on-site meeting, with 132958652 representative shares, accounting for 39.0956% of the total voting shares on the equity registration date of the company.
3. Online voting
There are 14 shareholders voting through the Internet, and the number of representative shares is 705200, accounting for 0.2074% of the total voting shares on the equity registration date of the company.
4. Small and medium-sized investors
A total of 15 minority shareholders and authorized representatives of shareholders attended the meeting, representing 715200 shares of the company, accounting for 0.2103% of the total voting shares on the equity registration date of the company.
Among them, one minority shareholder, shareholder representative and shareholder agent attended the on-site meeting, representing 10000 shares of the company, accounting for 0.0029% of the total voting shares on the equity registration date of the company;
A total of 14 minority shareholders, shareholder representatives and shareholder agents voted online, representing 705200 shares of the company, accounting for 0.2074% of the total voting shares on the date of equity registration of the company.
5. Directors, supervisors, senior managers, witness lawyers and other relevant personnel of the company attended the meeting. 4、 Deliberation and voting of proposals
The meeting adopted a combination of on-site voting and online voting.
1. The proposal on the company’s 2021 restricted stock incentive plan (Draft) and its summary was reviewed and adopted
Voting: 132958652 shares were approved, accounting for 99.4724% of the total number of valid voting shares attending the meeting; 705200 opposition shares, accounting for 0.5276% of the total number of valid voting shares attending the meeting; 0 shares abstained (including 0 shares abstained by default due to non voting), accounting for 0.00% of the total number of valid voting shares attending the meeting. Including: 10000 shares agreed by small and medium-sized investors, accounting for 1.3982% of the total voting shares of small and medium-sized investors attending the meeting; Oppose 705200 shares, accounting for 98.6018% of the total voting shares of small and medium-sized investors attending the meeting; 0 shares were abstained (including 0 shares by default due to non voting), accounting for 0.00% of the total voting shares of small and medium-sized investors attending the meeting.
This proposal is a special resolution, which has been approved by more than two-thirds of the total voting rights held by the shareholders who have attended the general meeting of shareholders and the authorized representatives of shareholders.
2. The proposal on the management measures for the assessment of the company’s restricted stock incentive plan in 2021 was reviewed and adopted
Voting: 132958652 shares were approved, accounting for 99.4724% of the total number of valid voting shares attending the meeting; 705200 opposition shares, accounting for 0.5276% of the total number of valid voting shares attending the meeting; 0 shares abstained (including 0 shares abstained by default due to non voting), accounting for 0.00% of the total number of valid voting shares attending the meeting. Including: 10000 shares agreed by small and medium-sized investors, accounting for 1.3982% of the total voting shares of small and medium-sized investors attending the meeting; Oppose 705200 shares, accounting for 98.6018% of the total voting shares of small and medium-sized investors attending the meeting; 0 shares were abstained (including 0 shares by default due to non voting), accounting for 0.00% of the total voting shares of small and medium-sized investors attending the meeting.
This proposal is a special resolution, which has been approved by more than two-thirds of the total voting rights held by the shareholders who have attended the general meeting of shareholders and the authorized representatives of shareholders.
3. The proposal on requesting the general meeting of shareholders to authorize the board of directors to handle matters related to the company’s restricted stock incentive plan in 2021 was deliberated and adopted
Voting: 132958652 shares were approved, accounting for 99.4724% of the total number of valid voting shares attending the meeting; 705200 opposition shares, accounting for 0.5276% of the total number of valid voting shares attending the meeting; 0 shares abstained (including 0 shares abstained by default due to non voting), accounting for 0.00% of the total number of valid voting shares attending the meeting. Including: 10000 shares agreed by small and medium-sized investors, accounting for 1.3982% of the total voting shares of small and medium-sized investors attending the meeting; Oppose 705200 shares, accounting for 98.6018% of the total voting shares of small and medium-sized investors attending the meeting; Abstain from 0 shares (including 0 shares by default due to non voting), accounting for 0.00% of the total voting shares of small and medium-sized investors attending the meeting.
This proposal is a special resolution, which has been approved by more than two-thirds of the total voting rights held by the shareholders who have attended the general meeting of shareholders and the authorized representatives of shareholders.
4. The proposal on adjusting the payment time of the remaining equity transfer funds for the sale of Fangzhou pharmaceutical was deliberated and adopted. The voting results: 133050052 shares were agreed, accounting for 99.5408% of the total number of valid voting shares attending the meeting; 613800 opposition shares, accounting for 0.4592% of the total number of valid voting shares attending the meeting; 0 shares abstained (including 0 shares abstained by default due to non voting), accounting for 0.00% of the total number of valid voting shares attending the meeting.
Among them, small and medium-sized investors agreed to 101400 shares, accounting for 14.1779% of the total voting shares of small and medium-sized investors attending the meeting; Against 613800 shares, accounting for 85.8221% of the total voting shares of small and medium-sized investors attending the meeting; 0 shares were abstained (including 0 shares by default due to non voting), accounting for 0.00% of the total voting shares of small and medium-sized investors attending the meeting.
5、 Legal opinions issued by lawyers
1. Name of law firm: Beijing Wanshang tianqin law firm
2. Name of Lawyer: Shi Youming, Xu Xiao
3. Conclusion: To sum up, our lawyers believe that the convening and convening procedures, the qualifications of participants and conveners, voting procedures and voting results of this general meeting of shareholders are in line with Chinese laws and regulations and the articles of association, and are legal and effective; There is no change or rejection of the proposal at the general meeting of shareholders of the company; The resolutions adopted at this shareholders’ meeting are legal and valid.
6、 Documents for future reference
1. Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) resolution of the first extraordinary general meeting of shareholders in 2022;
2. Legal opinion of Beijing Wanshang tianqin law firm on the first extraordinary general meeting of shareholders in Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) 2022 issued by Beijing Wanshang tianqin law firm.
It is hereby announced.
Jiangsu Lanfeng Bio-Chemical Co.Ltd(002513) board of directors January 18, 2022
